Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RPTX |
---|---|---|
09:32 ET | 8450 | 3.87 |
09:34 ET | 6918 | 3.81 |
09:36 ET | 1530 | 3.81 |
09:38 ET | 3606 | 3.82 |
09:39 ET | 300 | 3.858 |
09:41 ET | 8650 | 3.83 |
09:43 ET | 4383 | 3.82 |
09:45 ET | 2350 | 3.86 |
09:48 ET | 2954 | 3.81 |
09:50 ET | 2175 | 3.8 |
09:52 ET | 3570 | 3.7707 |
09:54 ET | 1964 | 3.8 |
09:56 ET | 700 | 3.8 |
09:57 ET | 1440 | 3.8 |
09:59 ET | 1710 | 3.8 |
10:01 ET | 263 | 3.8 |
10:03 ET | 500 | 3.8 |
10:06 ET | 308 | 3.8 |
10:08 ET | 930 | 3.8 |
10:10 ET | 1090 | 3.8 |
10:12 ET | 100 | 3.8 |
10:14 ET | 900 | 3.79 |
10:15 ET | 645 | 3.77 |
10:17 ET | 100 | 3.79 |
10:19 ET | 938 | 3.77 |
10:21 ET | 400 | 3.75 |
10:26 ET | 200 | 3.75 |
10:30 ET | 100 | 3.76 |
10:35 ET | 100 | 3.75 |
10:37 ET | 536 | 3.7413 |
10:39 ET | 600 | 3.73 |
10:42 ET | 1200 | 3.75 |
10:44 ET | 450 | 3.76 |
10:48 ET | 200 | 3.77 |
10:51 ET | 428 | 3.7514 |
11:00 ET | 950 | 3.7714 |
11:02 ET | 100 | 3.77 |
11:04 ET | 1000 | 3.77 |
11:08 ET | 746 | 3.77 |
11:09 ET | 200 | 3.78 |
11:11 ET | 100 | 3.79 |
11:13 ET | 200 | 3.79 |
11:15 ET | 1400 | 3.76 |
11:20 ET | 200 | 3.775 |
11:22 ET | 500 | 3.76 |
11:29 ET | 371 | 3.7612 |
11:31 ET | 300 | 3.76 |
11:33 ET | 1160 | 3.77 |
11:36 ET | 6002 | 3.78 |
11:38 ET | 2391 | 3.79 |
11:40 ET | 3322 | 3.8001 |
11:42 ET | 3139 | 3.8 |
11:44 ET | 3724 | 3.8 |
11:45 ET | 3661 | 3.8 |
11:47 ET | 7125 | 3.82 |
11:49 ET | 2104 | 3.835 |
11:51 ET | 6572 | 3.83 |
11:54 ET | 1298 | 3.85 |
11:56 ET | 1900 | 3.84 |
11:58 ET | 5711 | 3.83 |
12:00 ET | 1200 | 3.82 |
12:02 ET | 1800 | 3.83 |
12:03 ET | 600 | 3.83 |
12:05 ET | 200 | 3.82 |
12:09 ET | 3500 | 3.83 |
12:14 ET | 100 | 3.82 |
12:16 ET | 2600 | 3.83 |
12:18 ET | 1106 | 3.845 |
12:20 ET | 2879 | 3.83 |
12:21 ET | 390 | 3.825 |
12:27 ET | 5086 | 3.82 |
12:30 ET | 524 | 3.82 |
12:32 ET | 100 | 3.82 |
12:34 ET | 200 | 3.825 |
12:38 ET | 400 | 3.825 |
12:39 ET | 700 | 3.81 |
12:45 ET | 900 | 3.81 |
12:48 ET | 1624 | 3.81 |
12:50 ET | 100 | 3.81 |
12:52 ET | 1200 | 3.8 |
12:54 ET | 14728 | 3.79 |
12:56 ET | 100 | 3.8 |
12:59 ET | 600 | 3.795 |
01:01 ET | 404 | 3.7912 |
01:03 ET | 1100 | 3.78 |
01:12 ET | 200 | 3.75 |
01:15 ET | 100 | 3.77 |
01:19 ET | 279 | 3.765 |
01:21 ET | 100 | 3.765 |
01:24 ET | 254 | 3.7514 |
01:26 ET | 100 | 3.78 |
01:28 ET | 1332 | 3.76 |
01:33 ET | 1857 | 3.7599 |
01:37 ET | 400 | 3.77 |
01:39 ET | 300 | 3.76 |
01:44 ET | 1150 | 3.76 |
01:55 ET | 100 | 3.73 |
01:57 ET | 218 | 3.7314 |
02:00 ET | 200 | 3.76 |
02:08 ET | 1208 | 3.8 |
02:09 ET | 1300 | 3.78 |
02:15 ET | 100 | 3.79 |
02:22 ET | 700 | 3.78 |
02:24 ET | 400 | 3.76 |
02:26 ET | 1050 | 3.75 |
02:33 ET | 200 | 3.74 |
02:40 ET | 200 | 3.75 |
02:42 ET | 200 | 3.765 |
02:45 ET | 500 | 3.75 |
02:49 ET | 300 | 3.73 |
02:51 ET | 350 | 3.76 |
02:56 ET | 600 | 3.73 |
03:00 ET | 318 | 3.7318 |
03:02 ET | 200 | 3.76 |
03:05 ET | 1814 | 3.73 |
03:07 ET | 200 | 3.74 |
03:09 ET | 900 | 3.73 |
03:14 ET | 100 | 3.72 |
03:16 ET | 500 | 3.72 |
03:23 ET | 400 | 3.74 |
03:25 ET | 100 | 3.75 |
03:27 ET | 266 | 3.75 |
03:30 ET | 647 | 3.73 |
03:32 ET | 624 | 3.76 |
03:34 ET | 600 | 3.75 |
03:36 ET | 2424 | 3.75 |
03:38 ET | 100 | 3.76 |
03:39 ET | 1600 | 3.76 |
03:41 ET | 200 | 3.75 |
03:43 ET | 100 | 3.75 |
03:45 ET | 1641 | 3.76 |
03:48 ET | 100 | 3.75 |
03:50 ET | 500 | 3.78 |
03:52 ET | 1400 | 3.72 |
03:54 ET | 2000 | 3.71 |
03:56 ET | 2798 | 3.69 |
03:57 ET | 6171 | 3.71 |
03:59 ET | 4323 | 3.69 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Repare Therapeutics Inc | 157.0M | -3.4x | --- |
AVITA Medical Inc | 215.4M | -6.2x | --- |
Genfit SA | 181.7M | -5.9x | --- |
Precision BioSciences Inc | 79.5M | -1.1x | --- |
Champions Oncology Inc | 64.3M | -6.5x | --- |
Innate Pharma SA | 200.3M | -26.1x | --- |
Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on the development of synthetic lethality (SL)-based therapies for patients with cancer. The Company is engaged in the proprietary SL approach to the discovery and development of novel therapeutics. It uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The Company’s initial product candidate, camonsertib (RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated kinase (ATM) gene as part of a network of 16 STEP2-identified genomic alterations. Its other pipeline includes Lunresertib PKMYT1 Inhibitor and RP-3467 polymerase theta (Pol0) Inhibitor.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $157.0M |
---|---|
Revenue (TTM) | $97.9M |
Shares Outstanding | 42.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.74 |
EPS | $-1.10 |
Book Value | $5.03 |
P/E Ratio | -3.4x |
Price/Sales (TTM) | 1.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -72.27% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.